ACADIA to Host Conference Call and Webcast on Monday, March 9, 2009, at 5:00 p.m. Eastern Time
SAN DIEGO—(BUSINESS WIRE)—Mar. 2, 2009—ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will report its unaudited financial results for
the fourth quarter and year ended December 31, 2008 on Monday, March 9,
2009, after the U.S. financial markets close. ACADIA's management will
host a conference call and webcast on Monday, March 9, 2009, at 5:00
p.m. Eastern Time to discuss ACADIA’s financial results and development
programs.
The conference call may be accessed by dialing 866-700-0161 for
participants in the U.S. or Canada and 617-213-8832 for international
callers (reference passcode 63914388). A telephone replay of the
conference call may be accessed through March 23, 2009 by dialing
888-286-8010 for callers in the U.S. or Canada and 617-801-6888 for
international callers (reference passcode 11398116). The conference call
also will be webcast live on ACADIA’s website, www.acadia-pharm.com,
under the investors section and will be archived there until March 23,
2009.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for
central nervous system disorders. ACADIA is focused on developing a
portfolio of its four most advanced product candidates, including
pimavanserin in Phase III for Parkinson’s disease psychosis, a product
candidate in Phase II for chronic pain and a product candidate in Phase
I for glaucoma, both in collaboration with Allergan, and ACP-106 in
IND-track development. All of the product candidates in ACADIA’s
pipeline emanate from discoveries made using its proprietary drug
discovery platform. ACADIA maintains a website at www.acadia-pharm.com
to which ACADIA regularly posts copies of its press releases as well as
additional information and through which interested parties can
subscribe to receive email alerts.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director,
Investor Relations
Thomas H. Aasen, Vice President and Chief
Financial Officer
858-558-2871